Kestra Medical Technologies

Kirkland, WA, United States [4, 9, 10, 19, 21, 29]  All United States companies → Founded 2014
Medical Device / Hardware Specialty-Focused AI Wearables / RPM
Cardiology
Cardiology AI Wearables & Remote Monitoring (RPM)
Publicly Traded (IPO in 2025) [4, 5, 7, 9, 10, 24] — $428.00 M [7]

Products

ASSURE Wearable ECG
Kestra Medical Technologies
Cardiology AI
Kestra Medical Technologies offers the ASSURE Wearable ECG, a non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients.

See all 1 product →

About Kestra Medical Technologies

Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company dedicated to transforming patient outcomes in cardiovascular disease. The company focuses on developing and commercializing intuitive, intelligent, and connected diagnostic monitoring and therapeutic technologies. Its flagship offering, the ASSURE® Cardiac Recovery System, is a comprehensive platform designed to protect patients at risk of sudden cardiac arrest (SCA). [3, 5, 6, 14]

For physicians, the ASSURE system integrates a Wearable Cardioverter Defibrillator (WCD) for continuous multi-channel ECG monitoring, autonomous detection of life-threatening ventricular arrhythmias, and automatic defibrillation therapy. Beyond the therapeutic device, the system includes the Kestra CareStation™ remote patient data platform, which provides clinicians with relevant data, reports on arrhythmia episodes and usage trends, and configurable notifications. An accompanying ASSURE patient app empowers patients with educational resources, activity tracking, and seamless data transmission to their care teams, fostering collaboration and improved outcomes. [3, 6, 11, 14]

Kestra’s innovations are built on a foundation of deep expertise in Class III therapeutic medical devices, with an emphasis on patient experience through an “Empathy Powered Design” approach. The company aims to provide advanced medical solutions that empower both patients and healthcare providers, focusing on cardiovascular health and lifesaving medical technology, including addressing the unique needs of diverse patient populations like female cardiac patients. [3, 6, 14]

What Physicians Need to Know

Core Specialization
Kestra Medical Technologies specializes in wearable medical devices and digital healthcare, primarily focused on transforming patient outcomes in cardiovascular disease. Their core offering is the ASSUREu00ae Wearable Cardioverter Defibrillator (WCD) system, designed for sudden cardiac arrest (SCA) risk management and cardiac recovery through diagnostic monitoring and therapeutic intervention technologies.
Key Product
The ASSUREu00ae WCD system is a comprehensive platform that includes the wearable defibrillator, the ASSURE patient app, and the Kestra CareStationu2122 remote patient data platform. It offers integrated sensing, autonomous detection of life-threatening arrhythmias, and effective defibrillation therapy.
Patient-Centric Design
Kestra employs an 'Empathy Powered Designu2122' approach, prioritizing patient comfort, dignity, and ease of use. This design philosophy contributes to high patient compliance and significantly fewer false alarms compared to other wearable defibrillators.
Advanced Algorithms & AI
Their technology incorporates advanced algorithms for multi-channel ECG acquisition, signal processing, artifact reduction, and arrhythmia detection. The proprietary Adaptive Patient Intelligenceu2122 technology adapts to the patient's heart rhythm to filter out motion-induced artifacts, enhancing diagnostic accuracy.
Remote Monitoring Platform
The Kestra CareStationu2122 is a cloud-based remote patient data platform that provides healthcare providers with relevant data, detailed patient reports (including VT, VF, bradycardia, asystole, and non-sustained ventricular arrhythmia episodes), WCD usage, and physical activity trends, along with configurable notifications.
Strategic Collaborations
Kestra has a strategic collaboration with Biobeat Technologies to integrate Biobeat's FDA-cleared, cuffless, patch-worn ambulatory blood pressure monitoring (ABPM) device into the ASSURE WCD ecosystem. This expands diagnostic insight by providing continuous, non-invasive blood pressure data during cardiac recovery.
Physician Tip

For physicians, Kestra Medical Technologies stands out by offering a comprehensive Cardiac Recovery Systemu00ae that provides clear, actionable insights into patient heart rhythms and WCD usage. The integration of continuous blood pressure monitoring through the Biobeat collaboration offers enhanced diagnostic capabilities, supporting more informed clinical decision-making, especially for hypertensive cardiac patients. The system's patient-centric design aims for high compliance and fewer false alarms, reducing alert fatigue and improving the efficiency of care management. Furthermore, connected services like Heart Alertu2122 and ASSURE Assistu00ae facilitate seamless care coordination and emergency response, extending the reach of care teams for at-home patient support.

Kestra Medical Technologies' primary integration highlight is its strategic collaboration with Biobeat Technologies, which allows for the seamless incorporation of Biobeat's FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) data directly into Kestra's product portfolio for ASSURE WCD patients. This expands the diagnostic data available to care teams. Additionally, the Kestra CareStation platform is designed to integrate with emergency services dispatch for critical events.

Products by Kestra Medical Technologies

1 product in the directory

ASSURE Wearable ECG
Kestra Medical Technologies
Cardiology AI
Kestra Medical Technologies offers the ASSURE Wearable ECG, a non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients.

What the Web Says

Kestra Medical Technologies is a company specializing in wearable medical devices, particularly the ASSURE Wearable Cardioverter Defibrillator (WCD) system. The company receives high praise for its inclusive culture, strong management, and commitment to innovation and patient care. While product reviews highlight the user-friendliness and effectiveness of their WCD system, some concerns exist regarding competition and job security for certain roles. The company has been recognized as a Top Workplace in 2025 and 2026.

Overall: Mixed

Strengths

  • Excellent and inclusive company culture.
  • Solid management committed to making a difference.
  • Focus on innovation and patient outcomes.
  • ASSURE WCD system is user-friendly and effective with low false alarm rates.
  • Good work-life balance and pay/benefits.
  • Supportive and collaborative team environment.

Limitations

  • Product faces strong competition from established players like Zoll.
  • Some concerns about job security and steady salary for certain roles due to cost cuts.
  • Initial learning curve for Kestra's open-source workflow orchestration platform (if referring to Kestra, the software platform, not the medical device company).
  • Negative net margin and return on equity reported in recent financial results.
  • Stock downgraded to 'sell' by some analysts.

Based on reviews from: Indeed.com, Reddit, BioWorld, G2, PMC (PubMed Central), FlexJobs, USA Today

Last updated: 2026-07-18

Videos

News, demos, and interviews about Kestra Medical Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Kestra Medical Technologies →

View all on YouTube

Press & Coverage

Kestra Medical Technologies Investor Relations
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
Kestra Medical Technologies announced a five-year term loan facility with Pharmakon Advisors, LP, providing up to $200 million in non-dilutive financing to strengthen its balance sheet and support growth strategies.
2026-07
Kestra Medical Technologies Investor Relations
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
Kestra Medical Technologies partnered with Biobeat Technologies to integrate Biobeat's FDA-cleared 24-hour blood pressure monitoring into Kestra's ASSUREu00ae Wearable Cardioverter Defibrillator (WCD) system, aiming to provide expanded diagnostic insights for cardiac recovery patients.
2026-01
Kestra Medical Technologies Investor Relations
Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
Kestra Medical Technologies announced it would report its fourth quarter fiscal 2026 financial results on July 14, 2026, followed by a conference call to discuss the outcomes.
2026-06
Investing.com
Kestra Medical Technologies CEO Webster sells $336609 in stock
Brian Daniel Webster, President and CEO of Kestra Medical Technologies, sold common shares totaling $336,609 on July 15, 2026, under a Rule 10b5-1 trading plan.
2026-07
Kestra Medical Technologies Investor Relations
Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra's ASSURE Device
The ASSUREu00ae WCD Clinical Evaluation Post-Approval Study (ACE-PAS), the largest prospective real-world study of wearable defibrillators, confirmed the strong safety and effectiveness of Kestra's ASSURE WCD in clinical practice.
2025-11
Kestra Medical Technologies Investor Relations
Kestra Medical Technologies Announces Primary Public Offering of Common Shares
Kestra Medical Technologies announced an underwritten public offering of 5,500,000 common shares to support sales, marketing, commercialization, R&D, and general corporate purposes.
2025-12
MedAxiom
MedAxiom Announces Industry Partnership with Kestra Medical Technologies to Enhance Sudden Cardiac Arrest Risk Management
MedAxiom partnered with Kestra Medical Technologies to enhance sudden cardiac arrest risk management through Kestra's Cardiac Recovery System platform, which offers patient comfort, reliable event detection, and care coordination.
2025-10
FDA
510(k) Premarket Notification
The FDA granted Kestra Medical Technologies, Inc. a 510(k) Premarket Notification for its cardiovascular device, indicating it is substantially equivalent to a legally marketed device.
2024-05

Frequently Asked Questions

Kestra's Cardiac Recovery System, including the ASSURE Wearable Cardioverter Defibrillator (WCD), ASSURE patient app, and Kestra CareStation, utilizes advanced arrhythmia detection algorithms and cloud-based analytics to provide intelligent monitoring and therapeutic intervention. The CareStation platform delivers relevant data and insights into patient heart rhythms and usage compliance, aiding physicians in managing cardiac patient care.
Kestra's ASSURE WCD received FDA approval in July 2021, demonstrating its adherence to medical device regulations. The company explicitly states its compliance with HIPAA for patient data, and their systems are designed with secure, encrypted data transmission and robust compliance programs including ISO 13485, ISO 27001, and SOX.
Kestra Medical Technologies operates on a reimbursement-based model for its wearable cardioverter defibrillators, with an average Medicare reimbursement rate of approximately $3,519 per patient per month for WCDs. The ASSURE system has established reimbursement and broad insurance coverage in the U.S., simplifying the process for providers.
Kestra provides comprehensive support through its ASSURE Helpline for both patients and providers, along with a dedicated Kestra Careu2122 team for post-discharge assistance. The CareStation platform offers configurable notifications and a population dashboard, while connected services like Heart Alertu2122 and ASSURE Assistu00ae ensure timely clinical intervention and emergency support.
Kestra has formed key partnerships, including with Biobeat Technologies to integrate cuffless ambulatory blood pressure monitoring, and with MedAxiom to connect with the cardiovascular community. They also partnered with Bonafide (WellSky) for ERP to streamline operations and compliance, and GlobalLogic for software development and FDA clearance.
Kestra Medical Technologies is a commercial-stage, publicly traded company on NASDAQ (KMTS), demonstrating strong financial backing with a $196 million funding round in July 2024 and a $202 million IPO in March 2025. With over 33,000 patients having used their ASSURE WCD system and a leadership team with deep industry expertise, the company shows significant market presence and growth potential.
Kestra prioritizes patient data privacy by adhering strictly to HIPAA regulations, with all data transmitted securely and encrypted. Their arrhythmia detection algorithms are clinically validated, as evidenced by studies like ACE-PAS, which reported a low false alarm rate, ensuring reliability and reducing patient anxiety.

Investors

Who's funded Kestra Medical Technologies.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.